There are more PD-1 immune drugs, and the indications for each drug are not exactly the same. PD-1 inhibitors can play a therapeutic effect by blocking the PD-1 signaling pathway using monoclonal antibodies to PD-1 and restoring the immunocidal function of T cells. Currently, the commonly used PD-1 inhibitors in the clinic include navulizumab, pabolizumab and tirilizumab. The indications are not exactly the same. For example, the indications of Navulizumab mainly include non-small cell lung cancer, squamous cell carcinoma of the head and neck, and adenocarcinoma of the stomach or gastroesophageal junction. The indications of pembrolizumab are mainly melanoma, non-small cell lung cancer, colorectal cancer. The main indications for tirilizumab are classic Hodgkin’s lymphoma, uroepithelial carcinoma, non-small cell lung cancer, and hepatocellular carcinoma. PD-1 inhibitors can cause immune-related diseases, including pituitary inflammation, type 1 diabetes mellitus, diabetic ketoacidosis, hypothyroidism and hyperthyroidism; uveitis, arthritis, myositis, myocarditis, pancreatitis, Guillain-Barre syndrome, myasthenia gravis syndrome, hemolysis, anemia, tuberculosis, and encephalitis, and other adverse reactions. Contraindicated in people who are allergic to PD-1 inhibitors and their components, it is recommended to regulate the use of under the guidance of a doctor.PD-1 inhibitors can increase the risk of rejection of solid organ transplantation. PD-1 inhibitors have a wider scope of application and have the effect of delaying tumor development. It is recommended that patients follow the doctor’s instructions to standardize the use of drugs, do not blindly use drugs, so as not to cause adverse consequences.